Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
fda
life sciences
3
×
national blog main
alnylam pharmaceuticals
boston
boston blog main
boston top stories
drugs
onpattro
patisiran
rna interference
san francisco blog main
san francisco top stories
acute hepatic porphyrias
akcea therapeutics
akin akinc
aminolevulinic acid
andrew fire
cannabidiol
craig mello
dravet syndrome
epidiolex
fen-phen
fenfluramine
givosiran
gw pharmaceuticals
hereditary transthyretin amyloidosis
inotersen
john maraganore
lennox-gastaut syndrome
national top stories
new york blog main
new york top stories
nobel prize
paul matteis
pfizer
san diego blog main
san diego top stories
san francisco
What
drug
fda
3
×
medicine
pharmaceuticals
3
×
ago
alnylam
approved
rnai
weeks
afternoon
alnylam’s
approval
battle
cannabis
data
derivative
epilepsy
form
gets
gw
gw’s
history
indicated
interference
landmark
making
marijuana
market
nod
ok
onpattro
patisiran
quick
rare
rna
second
seek
sets
specifically
speedy
Language
Current search:
pharmaceuticals
×
fda
×
" life sciences "
×
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug